X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-03-01 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.02 | -2,519 | 160,098 | -2% | -$40,358 | |||||
| D | 2024-02-28 | NVCR | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale+OE | $16.14 | -2,078 | 162,617 | -1% | -$33,545 | |||||
| M | 2023-03-03 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.55 | -13,609 | 54,284 | -20% | -$1,028,165 | |||||
| M | 2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.95 | -2,903 | 67,893 | -4% | -$223,393 | |||||
2023-03-02 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.38 | -4,107 | 58,988 | -7% | -$309,578 | ||||||
| D | 2023-03-01 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $76.36 | -1,684 | 63,095 | -3% | -$128,594 | |||||
| D | 2023-01-05 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $112.25 | -39,507 | 46,158 | -46% | -$4,434,654 | |||||
2022-10-13 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.01 | -6,754 | 43,626 | -13% | -$513,372 | ||||||
2022-10-06 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $84.37 | -6,754 | 50,380 | -12% | -$569,835 | ||||||
2022-09-29 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.35 | -6,754 | 57,134 | -11% | -$522,422 | ||||||
2022-09-22 | NVCR | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.00 | -6,754 | 63,888 | -10% | -$520,058 | ||||||
| D | 2022-09-15 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale+OE | $88.52 | -12,271 | 70,642 | -15% | -$1,086,222 | |||||
| A | 2022-09-08 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $81.48 | -6,754 | 77,396 | -8% | -$550,316 | |||||
2022-09-09 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $88.00 | -1,863 | 84,150 | -2% | -$163,944 | ||||||
2022-09-06 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $78.57 | -1,384 | 86,013 | -2% | -$108,741 | ||||||
| M | 2022-09-01 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $77.50 | -14,796 | 87,397 | -14% | -$1,146,634 | |||||
2022-08-02 | NVCR | Leonard Frank X | Chief Development Officer | S - Sale | $69.66 | -414 | 102,193 | 0% | -$28,839 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |